Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics

Therapeutic Apheresis and Dialysis

Volumn 12, Issue SUPPL. 1, 2008, Pages

  Tominaga, Yoshihiro ^a   Matsuoka, Susumu ^a   Uno, Nobuaki ^a   Sato, Tetsuhiko ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Calcimimetics; Chronic kidney disease; Parathyroid hormone; Parathyroidectomy; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; PARATHYROID CARCINOMA; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PARATHYROMATOSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM; THYROID DISEASE;

CALCIUM; COST-BENEFIT ANALYSIS; ETHANOL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID GLANDS; PARATHYROIDECTOMY; PHOSPHORUS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 54949121752     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00627.x     Document Type: Conference Paper

References (12)

1. Block GA, Martin KJ, De Francisco ALM et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 : 1516 25.
2. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 2005 67 : 760 71.
3. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 1 : 78 86.
4. Tominaga Y, Inaguma D, Matsuoka S et al. Is the Volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006 10 : 198 204.
5. Tominaga Y, Matsuoka S, Sato K et al. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007 11 : 266 73.
6. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005 68 : 1793 800.
7. Kestenbaum B, Andress SL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004 66 : 2010 6.
8. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD. A cost utility analysis. Am J Kidney Dis 2007 49 : 801 13.
9. Tominaga Y, Matsuoka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005 9 : 44 7.
10. Matsuoka S, Tominaga Y, Sato T et al. Recurrent renal hyperparathyroidism caused by parathyromatosis. World J Surg 2007 31 : 299 305.
11. Tominaga Y, Tsuzuki T, Matsuoka S et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 2008 32 : 815 21.
12. Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007 92 : 3803 8.